Date: 2013-09-11
Type of information: Loan
Company: Oxford Biomedica (UK)
Investors: Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI) (UK)
Amount: £7.1 million (€ 8.4 million)
Funding type: award and loan
Planned used: The £7.7 million total funding award will support the development of a centre of excellence in ATMP supply chains in the UK with a focus on gene-based therapies at Oxford BioMedica. In particular, over the next two years the Company, supported by the consortium, will develop its capability in serum-free, non-adherent manufacturing techniques and expand its proprietary manufacturing facility in Oxford to contain a third production suite and a state-of-the-art fill and finish operation. The overall project cost is estimated at £9.2 million and is expected to take two years to complete.
Others: * On September 11, 2013, Oxford BioMedica, a gene-based biopharmaceutical company, has announced that it has been selected as a winner of a funding award under the UK Government’s Advanced Manufacturing Supply Chain Initiative (AMSCI), in recognition of the Company’s potential to become a world-leader in Advanced Therapy Medicinal Product (ATMP) manufacture and supply chain expertise. AMSCI was established to help existing UK supply chains grow and achieve world-class standards. The consortium wins £7.7 million total funding, of which £7.1 million awarded to Oxford BioMedica as lead member. Oxford BioMedica led the successful bid with four other UK-based participants: the Heart of England NHS Foundation, Cranfield University, Cell Therapy Catapult Ltd and Biotec Services International Ltd. Subject to due diligence and final confirmation by Birmingham City Council, the consortium has been awarded a £2.4 million grant, of which Oxford BioMedica will receive £1.8 million, and a £5.3 million loan to Oxford BioMedica which is repayable by March 2017.
Therapeutic area:
